CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice

Trial Profile

CAPRELSA REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa) in Current Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jul 2014 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top